The CE + FDA Strategic Combo: How Holding Both Approvals Unlocks 25+ Markets and Cuts Time-to-Market 30-50%

Why CE + FDA Together Is More Valuable Than Either Alone

Most medical device manufacturers treat CE marking and FDA 510(k) clearance as two separate regulatory projects. That framing misses the strategic picture. Holding both approvals simultaneously creates a multiplier effect that no single certification can match: more markets accessible, faster registration timelines in reliance jurisdictions, stronger negotiating leverage with distributors, and reduced country-by-country duplication.

This analysis is not about whether to pursue CE or FDA first — that decision depends on your commercial priorities. Instead, this is about what happens after you hold both, and why the combination unlocks significantly more than the sum of its parts.

As of 2026, the regulatory landscape increasingly favors manufacturers with dual approvals. The UK MHRA's March 2026 policy intent proposes recognition of both EU MDR CE marking and FDA approvals under its International Recognition framework (public consultation open through April 10, 2026). Singapore HSA accepts approvals from both reference agencies for abridged evaluation. Malaysia's MDA permanently confirmed its reliance pathway with Singapore (which itself relies on CE and FDA). The IMDRF Playbook for Regulatory Reliance, featured at the 29th IMDRF conference in Singapore in March 2026, further codifies this trend.

The Market Access Matrix: CE Only, FDA Only, or Both

The table below categorizes major medical device markets by which prior approval they accept and the mechanism through which access is granted.

Tier 1 — Full Reliance or Near-Automatic Acceptance

These markets will register your device based primarily on your existing CE or FDA approval, with minimal additional local requirements.

Tier 2 — Abridged or Expedited Review with CE or FDA

These countries accept CE or FDA as supporting evidence and offer a shorter review track, but still require a local dossier and often local testing or certification.

Tier 3 — Evidence Accepted But Full Local Review Required

CE or FDA approval supports your application but does not substitute for the local regulatory process.

Tier 4 — Reference Only, No Regulatory Shortcut

CE or FDA approval is considered but carries no formal legal shortcut. These markets require their own full review.

The Multiplier Effect: Country Count by Approval Combination

The key insight: many Tier 2 markets accept either CE or FDA. With both, you unlock every reliance pathway simultaneously rather than choosing between CE-dependent and FDA-dependent routes. More importantly, markets like Singapore offer an Expedited Route specifically for devices approved by two or more reference agencies — meaning dual CE+FDA holders can cut Singapore timelines from 4-9 months down to 2-4 months.

Concrete Timeline Comparisons

The following table shows real-world timeline differences for a Class II medical device pursuing registration in key markets, comparing three scenarios.

Aggregate time savings: For a manufacturer targeting the top 10 reliance markets simultaneously, holding dual CE+FDA approvals can reduce the average per-market registration timeline by 30-50% compared to pursuing each market with only one prior approval.

Cost Comparison: CE Only, FDA Only, or Both

The critical cost insight: since FDA's QMSR (effective February 2, 2026) incorporates ISO 13485:2016 by reference into 21 CFR Part 820, your quality management system now serves both CE and FDA compliance with a single audit framework. This eliminates one of the largest historical cost barriers to dual certification.

Strategic Decision Framework

When CE + FDA Makes Sense

• Your device targets both the EU and US markets commercially
• You plan to enter 5+ reliance markets in Asia-Pacific or Middle East
• Your competitors hold both approvals and you need parity
• Your device class benefits from expedited routes that require 2+ reference approvals (Singapore HSA Expedited Route)
• You want to diversify regulatory risk (NB capacity constraints in EU, FDA policy shifts in US)

When One May Suffice

• Your commercial focus is exclusively one region
• Your device is Class I or low-risk with minimal reliance benefit
• Budget constraints force prioritization (start with whichever market generates more revenue, add the second later)

Recommended Sequencing

Case Study: How Dual Approval Plays Out in Practice

Example: Class II Electrosurgical Unit

A manufacturer holds CE marking under EU MDR (Class IIb) and FDA 510(k) clearance (Class II).

Total: 10 major markets, with 8 accessible within 12 months of holding both approvals.

Without dual approval, the same manufacturer would face:

• Singapore: 4-9 months instead of 2-4 (no expedited route without 2 ref approvals)
• Malaysia: 4-6 months instead of ~3 (no Singapore reliance shortcut)
• Several markets: only one reference pathway available instead of two

The 2026 Regulatory Convergence Advantage

Several 2026 developments make the CE+FDA combination more powerful than ever:

1. FDA QMSR alignment with ISO 13485 (effective February 2, 2026): 21 CFR Part 820 now incorporates ISO 13485:2016 by reference, meaning a single QMS framework satisfies both CE and FDA quality system requirements. This was previously a major source of duplication.

2. UK MHRA International Recognition proposal (March 2026): The MHRA has proposed recognizing both EU MDR CE marking and FDA approvals under its International Recognition framework, with comparable regulator countries including the EU and US. This could make dual approval the key to seamless UK market access.

3. Singapore-Malaysia permanent reliance (March 2026): Malaysia's MDA permanently confirmed its verification route for devices on the Singapore Medical Device Register, creating a cascading pathway: CE → Singapore → Malaysia.

4. ASEAN single submission framework (proposed 2026): MDA has proposed a framework for a single submission accepted by four countries: Malaysia, Singapore, Thailand, and Indonesia. Dual CE+FDA approval positions manufacturers optimally for this framework.

5. ANVISA AREEs reliance initiative (IN 290/2024): Brazil's ANVISA is assessing why manufacturers underutilize regulatory reliance pathways. Dual CE+FDA holders are best positioned to benefit from future reliance expansions.

6. IMDRF Reliance Playbook (March 2026): The IMDRF conference codified best practices for regulatory reliance, further institutionalizing the acceptance of trusted prior approvals.

Bottom Line

Holding both CE marking and FDA approval is no longer just about accessing Europe and the United States. In 2026, it is the foundation for a global market access strategy that leverages regulatory reliance pathways across 25+ markets. The marginal cost of obtaining the second approval — particularly with QMS convergence under QMSR — is significantly lower than the first, while the incremental market access and timeline acceleration it unlocks far exceeds the additional investment.

For manufacturers serious about global scale, the question is no longer "CE or FDA?" but "how fast can we get the second one?"